Number of eligible patients: CDEC discussed the uncertainty in the volume of people with reasonably significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some sufferers who're classified as owning moderate or reasonable illness may have a intense bleeding phenotype, which https://hemgenix51593.wssblogs.com/35809527/the-best-side-of-hemgenix